Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis
Vonoprazan was well tolerated. Its safety profile from both clinical trial and post-marketing data were consistent and comparable to that of its PPI comparators with respect to treatment-emergent adverse events.
Authors
- Yu‐Ming Chang (ORCID: https://orcid.org/0000-0003-2431-1164)
- Stuart Jon Spechler (ORCID: https://orcid.org/0000-0001-5635-5386)
- Neila Smith
- Kenneth R. DeVault (ORCID: https://orcid.org/0000-0001-8156-5190)
- Philip O. Katz (ORCID: https://orcid.org/0000-0002-8021-0651)
- Colin W. Howden (ORCID: https://orcid.org/0000-0003-0987-0662)
- David C. Metz
- Barbara Hunt
- David Tamene
Institutions
- University of Tennessee Health Science Center (US)
- Cornell University (US)
- Jacksonville College (US)
- Baylor University Medical Center (US)
- Takeda (United States) (US)
- Mayo Clinic in Florida (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1111/apt.18458
- Citations
- 8
- Primary Topic
- Gastroesophageal reflux and treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.71